Comparative diagnosis of actinic keratosis (AK) and squamous cell carcinoma (SCC) in situ is needed for accuracy in treatment plan.
Laser-assisted drug delivery used to fractionally ablate the target area prior to topical medical treatment can be useful in patients with widespread actinic damage, says this expert.
Literature review shows that laser-assisted photodynamic therapy more efficacious than photodynamic therapy alone for actinic keratosis.
Topical 5‐fluorouracil is FDA-approved to treat actinic keratoses and superficial basal cell carcinoma, but it is commonly used off-label to treat a number of other skin conditions, such as squamous cell carcinoma despite strong evidence.
Reimbursements for actinic keratosis treatments are down slightly, but the demand for treatment is up by 20 percent.
Topical 5-fluorouracil (5-FU), which is FDA approved for treating actinic keratoses and superficial basal cell carcinoma, shows the strongest evidence of effectiveness for these two conditions plus squamous cell carcinoma, according to a comprehensive systematic review.
Study finds daylight photodynamic therapy with ablative fractional laser more effective than with microdermabrasion for treating actinic keratoses with large area field cancerization.
Is it just a “spot” or precancerous lesion? Two physicians debate how best to treat actinic keratosis in a talk given at EADV last week.
Lasers might allow the topical treatment of skin cancers with chemotherapy combinations that are currently given systemically, researchers say.